68ga-p16-093
Small moleculeexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2020 (NCT04796467)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Payload
- 68-gallium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07209865 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2024 | Fujian Medical University |
| NCT06049368 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2023 | Chinese Academy of Medical Sciences |
| NCT05324332 | N/A | Apr 15, 2022 | Chinese Academy of Medical Sciences |
| NCT05432947 | N/A | Apr 14, 2022 | Chinese Academy of Medical Sciences |
| NCT05569434 | Phase 1/Phase 2 (Phase 2) | Nov 28, 2021 | Chinese Academy of Medical Sciences |
| NCT04796467 | Early Phase 1 (Phase 1) | Oct 1, 2020 | Chinese Academy of Medical Sciences |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chinese Academy of Medical Sciences | Academic/Hospital | 5 | 5 | 3 | 2020 |
| Fujian Medical University | Academic/Hospital | 1 | 1 | 1 | 2024 |
2 organizations
Page 1 / 1